Cargando…

Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Higher afatinib plasma concentrations have been reported to be associated with the severity of diarrhea; however, the specific target plasma concentration of afatinib required to avoid severe diarrhea onset is unclear. We found that an afatinib AUC(0–24) of greater than or equal to 8...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yokota, Hayato, Sato, Kazuhiro, Sakamoto, Sho, Okuda, Yuji, Asano, Mariko, Takeda, Masahide, Nakayama, Katsutoshi, Miura, Masatomo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533256/ https://www.ncbi.nlm.nih.gov/pubmed/34681153 http://dx.doi.org/10.3390/biology10101054

Ejemplares similares

Eosinophil extracellular traps in a patient with chronic eosinophilic pneumonia
por: Takeda, Masahide, et al.
Publicado: (2021)

An autopsy case of anaplastic lymphoma kinase-positive lung cancer exacerbated in a short period of time: a case report
por: Takeda, Masahide, et al.
Publicado: (2019)

Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
por: Zhang, Li, et al.
Publicado: (2023)

High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction
por: Takahashi, Takayuki, et al.
Publicado: (2021)

Retroperitoneal Metastasis, with Marked Fibrosis, of Lung Adenocarcinoma after Afatinib Treatment: An Autopsy Case Report
por: Ota, Hiroki, et al.
Publicado: (2020)

A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety
por: Fukuhara, Tatsuro, et al.
Publicado: (2023)

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials
por: Hopkins, Ashley M., et al.
Publicado: (2018)

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)

Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells
por: Yoshioka, Takahiro, et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
por: Wind, Sven, et al.
Publicado: (2016)

“Liquid elbows” due to afatinib administration
por: Zarogoulidis, Paul, et al.
Publicado: (2017)

A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027
por: Minegishi, Yuji, et al.
Publicado: (2021)

Adenocarcinoma of the Lung Acquiring Resistance to Afatinib by Transformation to Small Cell Carcinoma: A Case Report
por: Nishimura, Jun, et al.
Publicado: (2017)

Effects of Alkalinization and Rehydration on Plasma Potassium Concentrations in Neonatal Calves with Diarrhea
por: Trefz, F.M., et al.
Publicado: (2015)

Successful Resection of G719X-Positive Pleomorphic Carcinoma after Afatinib Treatment
por: Nakamura, Daisuke, et al.
Publicado: (2017)

Afatinib in Non–Small Cell Lung Cancer
por: Wirth, Scott M.
Publicado: (2015)

Chinese Medicine Treatment for Afatinib-Induced Paronychia
por: Yang, Pei-Yuu, et al.
Publicado: (2017)

Afatinib use in recurrent epithelial ovarian carcinoma
por: Shepherd-Littlejohn, Amanda L., et al.
Publicado: (2019)

The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia
por: Taniguchi, Yasuhiro, et al.
Publicado: (2020)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer
por: Ozeki, Tomoko, et al.
Publicado: (2019)

Book Review: Understanding young onset dementia: Evaluation, needs and care
por: Sakamoto, Mariko
Publicado: (2023)

A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401)
por: Okajima, Masaaki, et al.
Publicado: (2021)

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
por: Schnell, David, et al.
Publicado: (2014)

Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

First reported case of afatinib‐associated toxic megacolon
por: Kwok, Wang Chun, et al.
Publicado: (2018)

Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
por: Nakamura, Tomomi, et al.
Publicado: (2018)

Efficacy and Safety Results of the Afatinib Expanded Access Program
por: Kim, Edward S., et al.
Publicado: (2017)

Fecal Viral Concentration and Diarrhea in Norovirus Gastroenteritis
por: Lee, Nelson, et al.
Publicado: (2007)

Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer
por: Ichiki, Masao, et al.
Publicado: (2017)

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
por: Oya, Yuko, et al.
Publicado: (2021)

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
por: Nishima, Shunichi, et al.
Publicado: (2020)

Hypereosinophilic syndrome with abundant Charcot-Leyden crystals in spleen and lymph nodes
por: Takeda, Masahide, et al.
Publicado: (2020)

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
por: Mita, Akiko, et al.
Publicado: (2018)

Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib
por: Hashida, Shinsuke, et al.
Publicado: (2015)

Evaluation of Serum 3‐Bromotyrosine Concentrations in Dogs with Steroid‐Responsive Diarrhea and Food‐Responsive Diarrhea
por: Sattasathuchana, P., et al.
Publicado: (2017)

Machine learning analysis to identify the association between risk factors and onset of nosocomial diarrhea: a retrospective cohort study
por: Kurisu, Ken, et al.
Publicado: (2019)

A Case of Abdominal Aortic Retroperitoneal and Mesenteric Amyloid Light Chain Amyloidoma
por: Yokota, Kazuhiro, et al.
Publicado: (2016)

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
por: Nelson, Valerie, et al.
Publicado: (2013)

Afatinib for the treatment of metastatic non-small cell lung cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dfaik8kilm356agii8t0qdlq82